Aequus Pharmaceuticals highlights new research showing Vistitan's effectiveness at treating glaucoma

Aequus Pharmaceuticals Inc (CVE:AQS) (OTCMKTS:AQSZF) updated shareholders on Friday on new research that highlights the effectiveness of the company’s Vistitan product in treating glaucoma. 

Results presented at the American Academy of Opthamology in San Franciso showed that bimatoprost 0.03%, marketed as Vistitan, is the most effective topical treatment to reduce intraocular pressure currently available for the eye disease. 

Vistitan reduces the pressure inside the eyes of patients with glaucoma and was first marketed by the pharmaceutical giant Sandoz. 

READ: Aequus Pharmaceuticals returns to revenue growth in second quarter

The study was conducted by Dr Paul Harasymowycz to assess the effectiveness of the opthalmic drug latanoprostene bunod compared to other treatments for intraocular pressure reduction after three months. 

Harasymowycz and his team found that bimatoprost 0.03% is the most successful treatment to reduce pressure and mitigate the risk of glaucoma. 

“In treating a disease where every millimetre of ocular pressure control is important, the data continues to support the use of Vistitan over the competition due to its effective bimatoprost 0.03% formulation,” said Ian Ball, CCO of Aequus in a statement.  

“This study adds to a growing body of evidence that Vistitan, the only bimatoprost 0.03% formulation currently marketed in Canada, is the most effective product available for treating glaucoma and is the cornerstone of our rapidly expanding ophthalmology franchise in Canada.” 

Vistitan is currently the only marketed version of 0.03% bimatoprost ophthalmic solution for glaucoma in Canada. 

Shares of Aequus traded at C$0.13 in Canada on Friday morning and US$0.10 on OTC markets. 

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Story by ProactiveInvestors